1
|
Magro F, Lopes S, Silva M, Coelho R, Portela F, Branquinho D, Correia L, Fernandes S, Cravo M, Caldeira P, Tavares de Sousa H, Patita M, Lago P, Ramos J, Afonso J, Redondo I, Machado P, Philip G, Lopes J, Carneiro F. Soluble human Suppression of Tumorigenicity 2 is associated with endoscopic activity in patients with moderate-to-severe ulcerative colitis treated with golimumab. Therap Adv Gastroenterol 2019; 12:1756284819869141. [PMID: 31516554 PMCID: PMC6719471 DOI: 10.1177/1756284819869141] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/24/2019] [Accepted: 07/17/2019] [Indexed: 02/04/2023] Open
Abstract
BACKGROUND Suppressor of Tumorigenicity 2 (ST2) is an IL33 receptor detected in the mucosa and serum of ulcerative colitis (UC) patients. We evaluated soluble ST2 (sST2) as a surrogate biomarker of disease outcome and therapeutic response, in moderate-to-severe UC patients treated with golimumab. METHODS We conducted an open-label single-arm multicentre prospective study. At screening/baseline, week 6 (W6) and week 16 (W16), clinical and endoscopic activity (total Mayo score), histologic activity (Geboes index) and biomarkers were evaluated. RESULTS From 38 patients, 34 (89.5%) completed W6 and 29 (76.3%) completed W16. Mean age (±SD) was 34.6 ± 12.6 years; 55.9% were female. At W16, 62.1% achieved clinical response. Patients with endoscopic activity at W6 (n = 20) had higher baseline sST2 (median, 24.5 versus 18.7 ng/ml, p = 0.026) and no decrease from baseline (median change, 0.8 versus -2.7, p = 0.029). At W6, sST2 levels correlated with endoscopic activity (rs = 0.45, p = 0.007) but not with histological activity (rs = 0.25, p = 0.151). The best cut-offs for endoscopic activity were sST2 = 16.9 ng/ml (sensitivity = 85%; specificity = 71%) and faecal calprotectin (FC) = 353 μg/g (sensitivity = 90%, specificity = 67%). Patients with histological activity at W6 (n = 27) had higher baseline ST2 levels (median, 23.0 versus 13.7 ng/ml, p = 0.035). sST2 did not correlate with FC or serum C-reactive protein. FC levels correlated with histological activity and baseline FC were higher when Geboes ⩾3.1 at W6. CONCLUSIONS sST2 may be a surrogate biomarker of UC activity and therapeutic response as it correlates with endoscopic and clinical activity at W6 of golimumab treatment, and subjects with endoscopic and histological activity at W6 had higher baseline ST2 levels.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | | | - Paulo Caldeira
- Centro Hospitalar Universitário do Algarve, Faro, Portugal
- Departamento de Ciências Biomédicas e Medicina, Universidade do Algarve, Faro, Portugal
- ABC–Algarve Biomedical Centre, Universidade do Algarve, Faro, Portugal
| | - Helena Tavares de Sousa
- Centro Hospitalar Universitário do Algarve, Faro, Portugal
- Departamento de Ciências Biomédicas e Medicina, Universidade do Algarve, Faro, Portugal
- ABC–Algarve Biomedical Centre, Universidade do Algarve, Faro, Portugal
| | | | - Paula Lago
- Centro Hospitalar do Porto, Porto, Portugal
| | - Jaime Ramos
- Centro Hospitalar Lisboa Central, Lisboa, Portugal
| | | | | | | | | | - Joanne Lopes
- Faculdade de Medicina, Universidade do Porto, Porto, Portugal
| | - Fátima Carneiro
- Faculdade de Medicina, Universidade do Porto, Porto, Portugal
- Instituto de Patologia e Imunologia Molecular da Universidade do Porto (Ipatimup), i3S-Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Porto, Portugal
| |
Collapse
|
2
|
Kercheva M, Ryabova T, Gusakova A, Suslova TE, Ryabov V, Karpov RS. Serum Soluble ST2 and Adverse Left Ventricular Remodeling in Patients With ST-Segment Elevation Myocardial Infarction. Clin Med Insights Cardiol 2019; 13:1179546819842804. [PMID: 31065219 PMCID: PMC6487275 DOI: 10.1177/1179546819842804] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/22/2018] [Accepted: 03/13/2019] [Indexed: 01/14/2023]
Abstract
Objective: To assess the dynamics of serum levels of soluble isoform of suppression of
tumorigenicity 2 (sST2) and N-terminal pro-brain natriuretic peptide
(NT-proBNP) and their correlations with the development of adverse left
ventricular remodeling (LVR) through 6 months in patients with primary
myocardial infarction with ST-segment elevation (STEMI). Methods: Subjects were 31 patients with STEMI (median age: 58 years), who underwent
percutaneous coronary intervention (PCI) during the first 24 hours of the
onset of myocardial infarction (MI). Blood samples and parameters of
echocardiography were assessed at days 1, 3, 7, and 14 and 6 months after
STEMI. Results: Serum levels of sST2 and NT-proBNP decreased during the 6-month period.
Levels of sST2 decreased by 48% from admission to day 7, and levels of
NT-proBNP decreased by 40% from day 7 to 6 months after STEMI. Serum levels
of sST2 at day 1 (r = 0.5, P < .05) and
day 3 (r = 0.4, P < .05) were
associated with adverse LVR by 6 months after STEMI. Logistic regression
analysis showed that a high concentration of sST2 at day 7 increased the
risk of adverse LVR (95% confidence interval [CI], 0.5-0.9; areas under
curve [AUC] = 0.8; P = .002), with 92% sensitivity and 70%
specificity. A multivariate analysis model revealed that adverse LVR was
associated with the level of sST2 (P = .003) and with
complete revascularization (P = .01) at the admission. Conclusions: The dynamics of serum levels of sST2 and NT-proBNP were different. The level
of sST2 normalized by the 7th day; NT-proBNP decreased only by the end of
the 6-month period after MI. Increased serum levels of sST2 by the 7th day
of MI were associated with the development of adverse LVR by the end of the
6-month period.
Collapse
Affiliation(s)
- Maria Kercheva
- Cardiology Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, Russian Federation
| | - Tamara Ryabova
- Cardiology Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, Russian Federation
| | - Anna Gusakova
- Cardiology Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, Russian Federation
| | - Tatiana E Suslova
- Cardiology Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, Russian Federation
| | - Vyacheslav Ryabov
- Cardiology Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, Russian Federation.,Siberian State Medical University, Tomsk, Russian Federation.,National Research Tomsk State University, Tomsk, Russian Federation
| | - Rostislav S Karpov
- Cardiology Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, Russian Federation.,Siberian State Medical University, Tomsk, Russian Federation
| |
Collapse
|